Psychedelics
Championing Female Representation in Canada’s Emerging Psychedelics Market
There is a global resurgence in the interest in psychedelics. With scientific, medical, and mental health communities revisiting its potential therapeutic benefits, psychedelics are being touted for its potential to treat addictions, mental health, cancer, amongst other ailments. This year alone, Canada experienced its most significant breakthrough with psychedelics after Minister of Health Patty Hajdu […]
MindMed Announces $25 Million Bought Deal Public Offering
Canada NewsWire NEW YORK, Nov. 25, 2020 /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./ NEW YORK, Nov. 25, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, […]
Delic Holdings Inc. (“ DELIC ” or the “ Company ”), a psychedelic-focused media, e-commerce and event company, is pleased to announce that effective at market open today, the Company will begin trading on the Canadian Securities Exchange under the ticker symbol “DELC.” Jackee Stang, CEO of DELIC comments “Canada has consistently shown leadership in […]
Psychedelic-Focused Media, E-Commerce and Event Company Delic Holdings Forms Advisory Board
Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC), a psychedelic-focused media, e-commerce and event company, is pleased to announce that it has formed an Advisory Board, to aid the company in its market diversification efforts to become the worldwide leader in operating and owning unique assets within the psychedelics sector. The purpose of the […]
Havn Life Sciences Announces $5.46 Million Warrant Exercise
Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (“Havn Life”) is pleased to announce that 10,927,856 common share purchase warrants (“Warrants”) have been exercised (“Exercise”), resulting in proceeds to the Company of $5.46 million. The Warrants had originally been issued by the Company pursuant to a private placement that closed on June 5, 2020 and were subject to […]
Toronto, Ontario–(Newsfile Corp. – November 23, 2020) – Pharmadrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“) applauds the recent approval by Germany’s Federal Institute of Drugs and Medical Devices (BfArM) of a study examining the Efficacy and Safety of Psilocybin in Treatment-Resistant Depression. This marks the first psilocybin depression study in Germany […]
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and […]
Novamind Closes Oversubscribed CAD$10 Million Private Placement
Hinterland Metals Inc. (”Hinterland”) and Novamind Ventures Inc. (”Novamind” or the ”Company”), a leading mental health and wellness company specialized in psychedelic-assisted psychotherapy, today announced that Novamind has closed an oversubscribed private placement of subscription receipts (the ”Financing”), raising aggregate gross proceeds of CAD$10.0 million, twice the original CAD$5.0 million target. With this latest round, […]
ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round
ATAI Life Sciences (“ATAI”), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C. The round was co-led by Apeiron Investment Group, […]
Peter Thiel backs Berlin start-up making psychedelics in $125 million round
Peter Thiel has led a $125 million funding round into a start-up aiming to make psychedelic drugs to treat mental health disorders. Total investment in the company now stands at over $210 million. Almost a billion people suffer from mental health problems worldwide, according to the World Health Organization. Peter Thiel Adam Jeffery | CNBC […]
Mind Medicine Australia Partners with Emyria
Mind Medicine Australia partners with Emyria (ASX: EMD) to develop national care program and data registry for psychedelic-assisted therapies Highlights: Emyria and Mind Medicine Australia to develop an evidenced based, best practice, model to support the safe and appropriate initiation, delivery and monitoring of psychedelic-assisted therapies in Australia Partnership will also develop a national clinical […]
Red Light Holland and Halo Labs Announce Intention to Enter Oregon Medicinal Psilocybin Market
TORONTO, Nov. 19, 2020 /CNW/ – Halo Labs Inc. (“Halo“) (NEO: HALO) (OTC: AGEEF) (Germany: A9KN) and Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland“) are pleased to announce they have entered into a non-binding letter of intent for the purposes of creating a joint venture to become a licensed psilocybin manufacturer to supply psilocybin […]
Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, and WHOOP, the human performance company, today announced a partnership whereby Field Trip will be using WHOOP Strap 3.0 to measure the biometric effects of Field Trip’s psychedelic therapies. Field Trip, which is opening […]
Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”or the “Company”) is pleased to announce that is has closed, on an oversubscribed basis, its previously announced non-brokered private placement (the “Offering“). The Company issued 8,000,000 units (the “Units“) at a price of $0.45 per Unit for gross proceeds of $3,600,000. Each Unit […]
NeonMind Commences Preclinical Trial to Examine Psilocybin for Weight
Vancouver, B.C. – November 19, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has now commenced a psilocybin preclinical trial examining psilocybin as a potential treatment to promote and cause weight loss and to reduce food […]
Psyched Wellness Ltd. Announces Insider Buying and Option Grant to Professor Nutt
Psyched Wellness Ltd. (CSE: PSYC) (OTC Pink: DCNPF) (formerly Duncan Park Holdings Corporation) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to inform investors that since commencing trading on the CSE on October 22, 2020, certain management and board members have […]
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has entered into an exclusive research collaboration agreement with Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused […]
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has announced it will undertake a compassionate access clinical trial of psilocybin-assisted psychotherapy for substance use disorders. This study will enable the company to implement, test, […]
Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) (“Field Trip”), a global leader in the development and delivery of technology-enabled psychedelic therapies, announced today that it has entered into a lease and plans to open a Field Trip Health Center in Amsterdam, Netherlands. Located at Piet Heinkade 55 overlooking the IJhaven River, the 665 sqm […]
Mydecine Innovations Group Offers Management and Clinical Trials Update
Dr. Rakesh Jetly Appointed Chief Medical Officer Company Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in Veterans VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, […]
Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety Disorders NEW YORK and BASEL, Switzerland, Nov. 16, 2020 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its protocol design for a Phase 2a […]
Lobe Sciences Commences Trading Under New Name and Announces Rebranding and Corporate Update
Lobe Sciences unveils new corporate name and logo as part of an extensive rebranding initiative, reflective of the Company’s focus on psychedelic medicines Vancouver, British Columbia–(Newsfile Corp. – November 16, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce that today it will commence trading on […]
Mind Cure Announces Non-Brokered Private Placement of $3 Million
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure”or the “Company”) wishes to announce that it will be conducting a non-brokered private placement to raise $3,000,000 (the “Offering“). The Offering will consist of up to 6,666,666 units at a price of $0.45 per unit (the “Units“). Each Unit will consist of one […]
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group […]
Havn Life Announces Launch of a Range of Natural Health Products
Havn Life Sciences Inc. (CNSX:HAVN) (FRA:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce its initial seven natural health supplements. These 7 products will be Havn Life’s first natural health products to launch […]
Prolific Parkinson’s Researcher Dr. Alberto J. Espay Joins Pharmather as Scientific Advisor
Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce the appointment of Dr. Alberto J. Espay, MD, MSc, FAAN, as a scientific and clinical advisor to the Company. Dr. Espay […]
Psyched Wellness Ltd. Applied to Up-List to the OTCQB and DTC Eligibility
Psyched Wellness Ltd. (CSE: PSYC) (OTC Pink: DCNPF) (formerly Duncan Park Holdings Corporation) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of artisanal functional mushrooms, is pleased to announce that it has applied to up-list its common stock to the OTCQB® Venture Marketplace and applied for DTC eligibility. The […]
COMPASS Pathways Plc Announces Financial Results For Third Quarter 2020
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter of 2020 and gave an update on recent progress across its business. George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, “This has been a […]
Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF)(“NOVA” or the “Company”) is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. (“Pilz”), has provided a corporate update. Dr. Marvin S. Hausman MD, Chairman and Chief Scientific Officer of Pilz commented: “We are very pleased with the progress that we have […]
Tryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific Officer
Tryp Therapeutics, a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. Jim Gilligan as President and Chief Scientific Officer. Dr. Gilligan brings over 30 years of drug development activities including pharmacology, preclinical activities, CMC manufacturing, clinical phase I-III, as well as […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
Pure Extracts is positioned to be the dominant extraction company to rapidly develop and commercialize functional and psychedelic medicine.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
